The impact of VEGF has been further explored in mouse models of AD using transgenic mice overexpressing VEGF or with brain administration of VEGF-releasing nanospheres or secreting cells, and showed an improvement in memory deficits, in vascularization and a decreased Aβ load (Spuch et al., 2010; Herrán et al., 2013; Religa et al., 2013; Garcia et al., 2014). This evidence concerns the gene VEGFA and Alzheimer disease.